Pfizer Ventures

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)inPLPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Co-investorsNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsCOCorrelation VenturesOROrbiMedOSOsage University PartnersOUOUP (Osage University Partners)+1 more

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

MGMichael Gilman(Executive Officer, Director)inMDMark DeLong(CEO)inDNDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

BoardCCColleen Cuffaro(Director)inAEAlan E. Walts(Director)in

Co-investorsCACanaan PartnersADAdvent Life SciencesNENextech InvestOUOUP (Osage University Partners)PFPfizer Venture InvestmentsVEvenBio Partners+1 more

Bio Protocol is a decentralized science (DeSci) platform where people can fund, develop and govern tokenized early-stage scientific research from universities, companies and researchers.

AI & Machine LearningBiotechCrypto & Web3

Co-investorsBIBinance LabsBIBig Brain HoldingsPOPolymorphic CapitalSESerafundSISignature VenturesSMSMAPE Capital+3 more

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

JAJim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)JSJacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNENexTech VenturesTHThird Rock VenturesNENextech InvestPFPfizer Venture InvestmentsSHShangBay Capital LLCAGAgent Capital

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.

BiotechHealthtechLeuven, BE

FGFederico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDRDroia VenturesVIVIBPFPfizer Venture InvestmentsPOPolaris Partners

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

RHRachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)MKMitchell Keegan(Chief Development Officer)inWLWilliam LaRochelle(Chief Scientific Officer)inSMStacy M. Plum(Chief Technology Officer)

Co-investorsSASanofi VenturesTATaiho Ventures, LLCSASamsara BioCapitalCACanaan PartnersCOConnecticut InnovationsPFPfizer Venture Investments+4 more

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

PTPatrick Trojer(President & Chief Executive Officer)in

Co-investorsASAscenta CapitalATAtlas VentureLILightspeed Venture PartnersRARA CapitalBEBessemer Venture PartnersFIFinchley Healthcare Ventures+3 more

TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.

BiotechDeep TechLongevityMedical DevicesCambridge, GB

Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)

Co-investorsCACambridge Innovation CapitalSVSV Health InvestorsPFPfizer Venture Investments

BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)

Co-investors5A5AM VenturesPFPfizer Venture Investments

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in

Co-investorsRARA CapitalSASamsara BioCapitalSVSV Health InvestorsPFPfizer Venture InvestmentsM M Ventures

Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform.

AI & Machine LearningBiotechDeep Tech

Yves Ribeill(CEO)

Co-investorsBPBpifranceELElaiaPFPfizer Venture Investments

EvolveImmune develops immunotherapy treatments for cancer patients.

BiotechHealthtechMedical Devices

Stephen Bloch(Co-founder and Chief Executive Officer)Jay Fine(President, Research and Development)

Co-investorsSOSolasta VenturesPFPfizer Venture Investments

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)

Co-investorsADAdvent Life SciencesGIGilde HealthcareINIndex VenturesMEMedicxiPFPfizer Venture Investments

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDRDroia VenturesVIVIBPFPfizer Venture Investments

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.

BiotechDigital HealthMedical Devices

Jim Broderick(Co-Founder)Li Peng(Chief Scientific Officer)Stefani Wolff(Chief Development Officer)

Co-investorsMAMatrix Capital ManagementPFPfizer Venture Investments

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsATAtlas VentureMIMission BiocapitalPFPfizer Venture InvestmentsPIPivotal Life Sciences

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

MMMax Mumbach(Founding Scientist, Target Discovery)inJVJeffrey Verboon(Founding Scientist, Computational Biology)inASAnsu Satpathy(Founder)KPKevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)ASAnsuman Satpathy, MD, PhD(Co-founder; Board Director)HCHoward Chang(Co-founder)in

Co-investors8V8VCANAndreessen HorowitzARArtis VenturesFIFinchley Healthcare VenturesGLGlobal BioAccess FundHAHAWKTAIL+7 more

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDWDmitri Wiederschain(Executive Officer)in

BoardACAlexandra Cantley(Director)inSakae Asanuma(Director)inBMBriggs Morrison(Executive Officer, Director, Promoter)inIMIrena Melnikova(Director)in

Co-investorsMPMPM BioImpactPFPfizer Venture InvestmentsBIBiotechnology Value FundMIMirae Asset Venture InvestmentPOPolaris PartnersTATaiho Ventures, LLC

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

NGNenad Grmusa(Chief Executive Officer)inJMJohn McCabe(Chief Financial and Operating Officer)in

Co-investorsALAlta PartnersASAstellas Venture Management LLCDCDC Investment PartnersLOLongwood FundPFPfizer Venture InvestmentsUTUTokyo Innovation Platform Co. Ltd.+1 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

KKKazuki Kamiya(CEO)SISatoru Ichihara(COO)SHShinya Hayashi(CSO)HIHidefumi Iwaki(CFO)TSTomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANANOBAKACACARTA VENTURES, Inc.SPSpiral VenturesAGAgent CapitalCACasdin CapitalINInvus+2 more

Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.

E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB

DPDaniel Parekh-Hill(CEO)inAlex Hooper(CTO)in

Co-investorsENEntrepreneur FirstAGAgent CapitalBABase10 PartnersCACasdin CapitalINInovia CapitalINInvus+3 more

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

PJPeter Joyce(Co-founder)inTMTom McCarthy(Co-founder)in

Co-investorsANAndera PartnersCACanaan PartnersOXOxford Science EnterprisesPFPfizer Venture InvestmentsBRBritish Patient CapitalEAEarlybird Venture Capital

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

DODaniel Olive(Founder)

Co-investorsAGAgent CapitalANAndera PartnersKUKurma PartnersPFPfizer Venture InvestmentsPUPureos BioventuresALAlexandria+4 more

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.

BiotechHealthtechMedical Devices

Co-investorsBIBioMedPartnersGIGimvLILightspeed Venture PartnersMIMission BiocapitalPFPfizer Venture InvestmentsREredalpine

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)PYPaul Yaworsky, PhD(CSO)inRBRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Co-investorsAGAgent CapitalGIGimvLOLongwood FundMIMission BiocapitalNONovartis Venture FundONOno Venture Investment, Inc.+4 more

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

MDMark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)CKCalvin Kuo(Scientific Co-Founder)KFKatie Fanning(President & Chief Executive Officer)in

Co-investorsARARCH Venture PartnersJDJDRF T1D FundMRMRL Ventures FundONOno Venture Investment, Inc.PFPfizer Venture InvestmentsSOSofinnova Partners+4 more

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM M VenturesOXOxford Science EnterprisesPFPfizer Venture InvestmentsBRBritish Patient CapitalJJJJDC

BiotechWaltham, US

James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)

BoardJens Eckstein(Director)

Co-investorsSRSR One Capital ManagementBIBioHealth Innovation, Inc.TATakeda VenturesVEVertex Ventures HC

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsCACambridge Innovation CapitalFAFast Track InitiativeM M VenturesPFPfizer Venture InvestmentsSESeroba Life SciencesTATaiho Ventures, LLC+1 more

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

BoardCOChristopher O'Donnell(Director)inDavid Rubin(Director)inJPJames Pavlik(Director)in

Co-investorsARArboretum VenturesPFPfizer Venture InvestmentsBABaird CapitalDEDeerfield Management CompanyMEMerck Global Health Innovation Fund